TFS
BMRN icon

Thoroughbred Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Thoroughbred Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,531
Closed -$244K – 482
2023
Q4 		$244K Sell
2,531
-53
-2% -$4.69K 0.02% 519
2023
Q3 		$228K Buy
+2,584
New +$230K 0.02% 511

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Thoroughbred Financial Services's BMRN Position: Q1 2024 in Review

Thoroughbred Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,531 shares — an estimated $244K sold.

Thoroughbred Financial Services first reported a position in BMRN in Q3 2023 and held it in 2 quarters. The position peaked at $244K in Q4 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Thoroughbred Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Thoroughbred Financial Services sold 2,531 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $244K.
  • Thoroughbred Financial Services first reported a position in BioMarin Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Thoroughbred Financial Services's BioMarin Pharmaceuticals position peaked at $244K in Q4 2023.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Thoroughbred Financial Services's 13F filing for Q1 2024, filed 7 May 2024.